Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)

被引:21
作者
Deconinck, E
Cahn, JY
Milpied, N
Jouet, JP
Vernant, JP
Esperou, H
Lioure, B
Bordigoni, P
Leblond, V
Troussard, X
Caillot, D
Cordonnier, JM
Herve, P
机构
[1] CHU BESANCON,HOP JEAN MINJOZ,SERV HEMATOL,DEPT HEMATOL,F-25030 BESANCON,FRANCE
[2] CHU BESANCON,HOP JEAN MINJOZ,BMT UNIT,F-25030 BESANCON,FRANCE
[3] HOP HOTEL DIEU,BMT UNIT,NANTES,FRANCE
[4] HOP HOTEL DIEU,DEPT HEMATOL,NANTES,FRANCE
[5] HOP OSCAR LAMBRET,BMT UNIT,LILLE,FRANCE
[6] HOP OSCAR LAMBRET,DEPT HEMATOL,LILLE,FRANCE
[7] HOP HENRI MONDOR,BMT UNIT,F-94010 CRETEIL,FRANCE
[8] HOP HENRI MONDOR,DEPT HEMATOL,F-94010 CRETEIL,FRANCE
[9] HOP ST LOUIS,BMT UNIT,PARIS,FRANCE
[10] HOP ST LOUIS,DEPT HEMATOL,PARIS,FRANCE
[11] HOP HAUTE PIERRE,BMT UNIT,STRASBOURG,FRANCE
[12] HOP HAUTE PIERRE,BMT UNIT,STRASBOURG,FRANCE
[13] HOP HAUTE PIERRE,DEPT HEMATOL,STRASBOURG,FRANCE
[14] HOP ENFANT BRABOIS,BMT UNIT,NANCY,FRANCE
[15] HOP ENFANT BRABOIS,DEPT HEMATOL,NANCY,FRANCE
[16] HOP LA PITIE SALPETRIERE,BMT UNIT,PARIS,FRANCE
[17] HOP LA PITIE SALPETRIERE,DEPT HEMATOL,PARIS,FRANCE
[18] HOP UNIV,BMT UNIT,CAEN,FRANCE
[19] HOP UNIV,DEPT HEMATOL,CAEN,FRANCE
[20] HOP BOCAGE,BMT UNIT,DIJON,FRANCE
[21] HOP BOCAGE,DEPT HEMATOL,DIJON,FRANCE
关键词
acute lymphoblastic leukemia; bone marrow transplantation; total body irradiation; cytosine arabinoside; melphalan;
D O I
10.1038/sj.bmt.1700964
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Attempts to improve the efficacy of pretransplant conditioning regimens have been published, the potential of a better antileukemic effect being impaired by more frequent and severe toxicities, The efficacy of an intensified regimen, TAM (TBI, high-dose cytosine arabinoside and melphalan), is evaluated by analysing long-term follow-up of a homogenous group of 42 high-risk ALL patients allografted in first CR, Age at time of BMT was 25.9 +/- 10.4 years (3-41), Twenty-two patients had more than three adverse prognostic factors, Ten patients had a Ph chromosome, Probability of overall survival was 45 +/- 9%, and for all surviving patients median followup time was 66 months, Event-free survival was 40 +/- 8% at 7 years after transplantation and the expected relapse rate reached 31%, Twenty-two deaths occurred, six after a relapse but 16 appeared to be directly due to the BMT procedure, None of the pretransplant characteristics significantly affected outcome after BMT. TAM appeared to be an efficient antileukemic therapy for conditioning high-risk ALL patients before allogeneic transplantation, but was still very toxic, The use of TAM in adult ALL patients in first CR is not recommended and the real role of intensified conditioning regimens remains to be demonstrated.
引用
收藏
页码:731 / 735
页数:5
相关论文
共 40 条
[1]   CONSOLIDATION TREATMENT OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A PROSPECTIVE, RANDOMIZED TRIAL COMPARING ALLOGENEIC VERSUS AUTOLOGOUS BONE-MARROW TRANSPLANTATION AND TESTING THE IMPACT OF RECOMBINANT INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
ATTAL, M ;
BLAISE, D ;
MARIT, G ;
PAYEN, C ;
MICHALLET, M ;
VERNANT, JP ;
SAUVAGE, C ;
TROUSSARD, X ;
NEDELLEC, G ;
PICO, J ;
HUGUET, F ;
STOPPA, AM ;
BROUSTET, A ;
SOTTO, JJ ;
PRIS, J ;
MARANINCHI, D ;
REIFFERS, J .
BLOOD, 1995, 86 (04) :1619-1628
[2]  
BARRETT AJ, 1989, BLOOD, V74, P862
[3]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[4]   ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA DURING 1ST COMPLETE REMISSION [J].
BLUME, KG ;
FORMAN, SJ ;
SNYDER, DS ;
NADEMANEE, AP ;
ODONNELL, MR ;
FAHEY, JL ;
KRANCE, RA ;
SNIECINSKI, IJ ;
STOCK, AD ;
FINDLEY, DO ;
LIPSETT, JA ;
SCHMIDT, GM ;
NATHWANI, MB ;
HILL, LR ;
METTER, GE .
TRANSPLANTATION, 1987, 43 (03) :389-392
[5]  
BORDIGONI P, 1991, BLOOD, V10, P78
[6]  
CAHN JY, 1991, BONE MARROW TRANSPL, V7, P1
[7]  
CAHN JY, 1988, BONE MARROW TRANSPL, V3, P187
[8]  
CAHN JY, 1987, AUTOLOGOUS BONE MARR, V3, P601
[9]  
CHAMPLIN R, 1985, SEMIN ONCOL, V12, P190
[10]  
CHAO NJ, 1991, BLOOD, V78, P1923